{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:13:03Z","timestamp":1794323583254,"version":"4.9.0"},"reference-count":27,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3111\/13696998.2013.820192","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T12:03:30Z","timestamp":1372421010000},"page":"1120-1128","source":"Crossref","is-referenced-by-count":17,"title":["Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis"],"prefix":"10.3111","volume":"16","author":[{"given":"Machaon","family":"Bonafede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Princic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2013,7,18]]},"reference":[{"key":"CIT0004","volume-title":"Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (NICE technology appraisal guidance 130)","author":"National Institute for Health and Clinical Excellence","year":"2007"},{"key":"CIT0006","volume-title":"Adalimumab for the treatment of adults with psoriasis (NICE technology appraisal guidance 146)","author":"National Institute for Health and Clinical Excellence","year":"2008"},{"key":"CIT0007","volume-title":"Infliximab for the treatment of adults with psoriasis (NICE technology appraisal guidance 134)","author":"National Institute for Health and Clinical Excellence","year":"2008"},{"key":"CIT0008","volume-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (NICE technology appraisal guidance 199)","author":"National Institute for Health and Clinical Excellence","year":"2010"},{"key":"CIT0009","volume-title":"Adalimumab, etanercept and infliximab for ankylosing spondylitis (NICE technology appraisal guidance 143)","author":"National Institute for Health and Clinical Excellence","year":"2008"},{"key":"CIT0010","first-page":"47","volume":"19","author":"Bullano MF","year":"2006","journal-title":"Manag Care Interface"},{"key":"CIT0011","first-page":"21","volume":"18","author":"Etemad L","year":"2005","journal-title":"Manag Care Interface"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-5-36"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.04.002"},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3111\/13696998.2011.649325","volume":"15","author":"Carter CT","year":"2012","journal-title":"J Med Econ"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090487"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80063-X"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X210615"},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0149-2918(05)00090-1","volume":"27","author":"Weycker D","year":"2005","journal-title":"Clin Ther"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-012-0007-y"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.644645"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2191-1991-2-20","volume":"2","author":"Zeidler J","year":"2012","journal-title":"Health Econ Rev"},{"key":"CIT0022","volume-title":"Employer Health Benefits: 2012 Annual Survey","author":"Claxton G","year":"2012"},{"key":"CIT0025","first-page":"26","volume":"29","author":"Moots RJ","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090054"},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1185\/03007995.2012.656844","volume":"28","author":"Schabert VF","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3111\/13696998.2012.667028","volume":"15","author":"Bonafede MM","year":"2012","journal-title":"J Med Econ"},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"Bartelds GM","year":"2011","journal-title":"JAMA"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1002\/art.21582"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G264"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802229548"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-204"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2013.820192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T11:26:12Z","timestamp":1498044372000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2013.820192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,18]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,7,9]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3111\/13696998.2013.820192"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2013.820192","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,18]]}}}